T. Rowe Price Associates
LRMR icon

T. Rowe Price Associates’s Larimar Therapeutics LRMR Stock Holding History

T. Rowe Price Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
34,768
+5,760
+20% +$23K ﹤0.01% 2903
2025
Q4 		$111K Buy
29,008
+6,038
+26% +$23.5K ﹤0.01% 2931
2025
Q3 		$75K Buy
22,970
+1,669
+8% +$6.26K ﹤0.01% 2969
2025
Q2 		$62K Buy
21,301
+4,991
+31% +$11.6K ﹤0.01% 2974
2025
Q1 		$36K Buy
16,310
+858
+6% +$2.71K ﹤0.01% 2965
2024
Q4 		$60K Buy
15,452
+1,992
+15% +$13.1K ﹤0.01% 2907
2024
Q3 		$89K Hold
13,460
– – ﹤0.01% 2842
2024
Q2 		$98K Buy
+13,460
New +$103K ﹤0.01% 2762
2019
Q3 		– Sell
-3,901
Closed -$56K – 2536
2019
Q2 		$56K Sell
3,901
-42
-1% -$1.12K ﹤0.01% 2510
2019
Q1 		$130K Sell
3,943
-68,617
-95% -$3.52M ﹤0.01% 2449
2018
Q4 		$4.31M Sell
72,560
-31,147
-30% -$3.07M ﹤0.01% 1420
2018
Q3 		$14.5M Buy
+103,707
New +$12.6M ﹤0.01% 1308
2017
Q1 		– Sell
-5,910
Closed -$226K – 2585
2016
Q4 		$226K Sell
5,910
-11
-0.2% -$446 ﹤0.01% 2348
2016
Q3 		$235K Hold
5,921
– – ﹤0.01% 2305
2016
Q2 		$426K Sell
5,921
-946
-14% -$74.8K ﹤0.01% 2024
2016
Q1 		$550K Sell
6,867
-1,997
-23% -$158K ﹤0.01% 1930
2015
Q4 		$669K Sell
8,864
-28,418
-76% -$4.56M ﹤0.01% 1834
2015
Q3 		$14.3M Sell
37,282
-5,351
-13% -$2.41M ﹤0.01% 1207
2015
Q2 		$17.7M Sell
42,633
-1,747
-4% -$731K ﹤0.01% 1174
2015
Q1 		$21.1M Buy
+44,380
New +$21.1M ﹤0.01% 1113

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates's LRMR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Larimar Therapeutics (LRMR) stake by 20% in Q1 2026, buying an estimated $23K and bringing the position to 34,768 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

T. Rowe Price Associates first reported a position in LRMR in Q1 2015 and has held it in 20 quarters since. The position peaked at $21.1M in Q1 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • T. Rowe Price Associates held 34,768 shares of Larimar Therapeutics worth $157K as of Q1 2026.
  • T. Rowe Price Associates bought 5,760 Larimar Therapeutics shares in Q1 2026, an estimated $23K.
  • Larimar Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2903 holding.
  • T. Rowe Price Associates first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Larimar Therapeutics position peaked at $21.1M in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.